Inovio Pharmaceuticals: Maintaining Buy Rating Amid BLA Submission Delay
Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
Inovio Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
Inovio Pharmaceuticals Receives 'Buy' Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals: Hold Rating Amidst Clinical Progress and Financial Caution
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals: Hold Rating With Promising Pipeline Despite Financial Losses
RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)
Inovio Upgraded at Oppenheimer on Rare Disease Therapy
Inovio Pharmaceuticals Analyst Ratings
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target
JMP Securities Initiates Coverage On Inovio Pharmaceuticals With Market Outperform Rating, Announces Price Target of $1
Inovio Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
Analysts Offer Insights on Healthcare Companies: Vertex (VERX), Inovio Pharmaceuticals (INO) and Pliant Therapeutics (PLRX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Inovio Pharmaceuticals (INO)